Invention Grant
- Patent Title: Antibody drug conjugates for ablating hematopoietic stem cells
-
Application No.: US17833077Application Date: 2022-06-06
-
Publication No.: US12171839B2Publication Date: 2024-12-24
- Inventor: Anthony Edward Boitano , Matthew Burger , Susan E. Cellitti , Michael P. Cooke , Catrin Finner , Bernhard Hubert Geierstanger , Yunho Jin , Si Tuen Lee-Hoeflich , HongNgoc Thi Pham , Siew Ho Schleyer , Kathrin Tissot , Tetsuo Uno , Ben Wen
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agency: K&L Gates LLP
- Main IPC: C07K16/00
- IPC: C07K16/00 ; A61K38/07 ; A61K38/12 ; A61K47/68 ; C07K16/28 ; C07K16/46

Abstract:
The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
Public/Granted literature
- US20220305134A1 ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS Public/Granted day:2022-09-29
Information query